EWEmil Winther Westi

Emil Winther Westi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emil Winther Westi has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Blanca Irene Aldana

    Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

    7 shared publications
  • Jens Velde Andersen

    Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

    6 shared publications
  • Belén García Sintes

    Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

    2 shared publications
  • Dana Alnajar

    Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

    2 shared publications
  • Filippa Liliendahl Qvist

    Affiliations Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark, NNF Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark

    2 shared publications
  • Niels Henning Skotte

    Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark

    2 shared publications

Latest Publications

  • Open Access

    Sex-dependent investigations of the temporal development of infarct size and blood-brain barrier permeability after photothrombotic stroke in mice – a pilot study

    by Maria Thaysen, Natalia Łopuszyńska, Emil Winther Westi, Petrine Wellendorph, Lotte Kellemann Kristensen, Mie Kristensen

  • Open Access

    Metabolic Flexibility of Microglia: Energy Substrate Utilization and Impact on Neuronal Metabolism

    by Emil W. Westi, Rebecca Birch Carlsen, Jens Velde Andersen, Zeliha Kilic, Dana Alnajar, Nadia K. Holmgaard, Belén García Sintes, Agustin Cota‐Coronado, Sonia Sanz Muñoz, Céline Galvagnion, et al.

    Microglia, the main resident immune cells of the brain, play critical roles in maintaining neuronal function and homeostasis. Microglia's metabolic flexibility enables rapid adaptation to environmental changes, yet the full extent of their metabolic capabilities and influence on neuronal metabolism remains unclear. While microglia predominantly rely on glucose oxidative metabolism under homeostatic conditions, they shift towards glycolysis upon proinflammatory activation. In this study, we investigated microglial metabolism and its impact on neuronal metabolic homeostasis using isotope tracing with stable carbon 13 C‐enriched substrates and gas chromatography–mass spectrometry (GC–MS) analysis. Primary microglia were incubated with 13 C‐labeled glucose, glutamine, or GABA in the presence or absence of lipopolysaccharide (LPS) to assess metabolic adaptations upon an inflammatory challenge. Additionally, neurons co‐cultured with quiescent or activated microglia (either with LPS or amyloid‐β) were incubated with 13 C‐enriched glucose to examine microglia–neuron metabolic interactions. Our findings confirm that microglia readily metabolize glucose and glutamine, with LPS stimulation slightly changing the glycolytic activity, as indicated by subtle changes in extracellular lactate. Importantly, we demonstrate for the first time that microglia take up and metabolize the inhibitory neurotransmitter GABA, suggesting a novel metabolic function. Furthermore, microglial presence directly influences neuronal metabolism and neurotransmitter homeostasis, highlighting a previously unrecognized aspect of neuron–microglia metabolic crosstalk. Collectively, these findings provide new insights into microglial metabolism and its role in neuronal function, with implications for neuroinflammatory and neurodegenerative diseases in which microglial metabolism is dysregulated. image


  • Open Access

    Metabolic Flexibility of Microglia: Energy Substrate Utilization and Impact on Neuronal Metabolism

    by Emil W. Westi, Rebecca Birch Carlsen, Jens Velde Andersen, Zeliha Kilic, Dana Alnajar, Nadia K Holmgaard, Belén García Sintes, Agustin Cota-Coronado, Sonia Sanz Muñoz, Céline Galvagnion, et al.

    Microglia, the main resident immune cells of the brain, play critical roles in maintaining neuronal function and homeostasis. Microglia metabolic flexibility enables rapid adaptation to environmental changes, yet the full extent of their metabolic capabilities and influence on neuronal metabolism remains unclear. While microglia predominantly rely on glucose oxidative metabolism under homeostatic conditions, they shift toward glycolysis upon proinflammatory activation. In this study, we investigated microglial metabolism and its impact on neuronal metabolic homeostasis using isotope tracing with stable carbon 13 C-enriched substrates and gas chromatography-mass spectrometry (GC-MS) analysis. Primary microglia were incubated with 13 C-labeled glucose, glutamine, or GABA in the presence or absence of lipopolysaccharide (LPS) to assess metabolic adaptations upon an inflammatory challenge. Additionally, neurons co-cultured with quiescent or activated microglia (either with LPS or amyloid-β) were incubated with 13 C-enriched glucose to examine microglia-neuron metabolic interactions. Our findings confirm that microglia readily metabolize glucose and glutamine, with LPS stimulation slightly changing the glycolytic activity, as indicated by subtle changes in extracellular lactate. Importantly, we demonstrate for the first time that microglia take up and metabolize the inhibitory neurotransmitter GABA, suggesting a novel metabolic function. Furthermore, microglial presence directly influences neuronal metabolism and neurotransmitter homeostasis, highlighting a previously unrecognized aspect of neuron-microglia metabolic crosstalk. Collectively, these findings provide new insights into microglial metabolism and its role in neuronal function, with implications for neuroinflammatory and neurodegenerative diseases in which microglial metabolism is dysregulated.


  • Open Access

    Distinct and Combined Interferon-ɑ/β-receptor-1 Loss in Neurons and Astrocytes Disrupt Brain Energy Metabolism and Drive Parkinsonian Dementia

    by Erika B. Villanueva, Zala Zebec, Jon Lundstrøm, Jens V. Andersen, Filippa L. Qvist, Emil W. Westi, Andrea Marin, Gisela Jimenez-Duran, Lluís Riera-Ponsati, Emilie Tresse, et al.

    Dysregulated interferon-alpha/beta-receptor 1 (IFNAR1) signaling was recently identified to contribute to the development of sporadic Parkinson’s Disease (PD) into PD with Dementia (PDD). The molecular, cellular, and phenotypic impacts of brain IFNAR1 loss in aging have not been explored in vivo , which may reveal novel disease mechanisms and therapeutic targets. Here it is shown that baseline IFNAR1 expression varies in the major brain cell types, including neurons and astrocytes, and is differentially affected in PD and Lewy Body Dementia patients compared to unaffected controls. Neuron- and astrocyte-specific transcriptomic and proteomic alterations in Ifnar1 −/− mice implicate mitochondrial defects and synergistic dysfunctional neurotransmission upon IFNAR1 loss, leading to glucose hypermetabolism measured by functional metabolic analysis. Consequently, Ifnar1 −/− mice exhibited PDD-like pathogenesis, including dopaminergic cell loss in the substantia nigra, cortical neurodegeneration, Lewy-body-like inclusions, neuroinflammation, and progressive PDD-like behavior deficits. Brain cell-specific IFNAR1 loss examined in vivo revealed delayed but distinct development of PDD-like phenotypes, where neuropathology, motor, and cognitive behavior deficits were specifically recapitulated only in mice lacking neuronal IFNAR1, and behavior resembling neuropsychiatric abnormalities recapitulated only in mice lacking astrocytic IFNAR1. This work supports a crucial role of IFNAR1 in brain homeostasis and emphasizes a need for understanding neurodegenerative pathophysiology in cell-specific contexts. Highlights: IFNAR1 and related type-I IFN genes are differentially expressed among major brain cell types in Parkinson’s Disease, Lewy Body Dementia, and unaffected controls Early molecular alterations in Ifnar1 −/− mice show lack of immunomodulation contributing to neuroinflammation, mitochondrial defects, and dysregulated energy metabolism Ifnar1 −/− mice develop a progressive Parkinsonian-like disease phenotype, including dopaminergic cell loss in substantia nigra, cortical neurodegeneration, phosphorylated (p)alpha-synuclein + and pTau + Lewy-body-like inclusions, neuroinflammation, and progressive motor, cognitive, and neuropsychiatric disturbance-like behavior deficits Neuropathologies, motor, and cognitive deficits are recapitulated in mice lacking neuronal IFNAR1 (Syn1 Cre ; Ifnar1 fl/fl ) whereas neuropsychiatric abnormalities are recapitulated in mice lacking astrocytic IFNAR1 (GFAP Cre ; Ifnar1 fl/fl )

  • Top Cited Papers
    Open Access

    Choroid plexus-mediated CSF secretion remains stable in aging rats via high and age-resistant metabolic activity

    by Sara D. Lolansen, Eszter O. Révész, Søren N. Andreassen, Marleen Trapp, Chiara Salio, Marco Sassoé-Pognetto, Jens Velde Andersen, Emil W. Westi, Trine L. Toft-Bertelsen, Jonathan H. Wardman, et al.

    Our brain is bathed in cerebrospinal fluid (CSF) that is produced by the choroid plexus. CSF serves as a dispersion route for hormones and nutrients, and a conduit for waste clearance. Age-dependent reduction in the CSF secretion rate could influence cerebral waste clearance and thereby promote cognitive deficits in the elderly. Here, we resolve age-dependent modulation of CSF dynamics and choroid plexus function by complementary in vivo determinations of intracranial pressure (ICP) and CSF secretion/absorption rates, combined with transcriptomic, morphological, and metabolic analysis of choroid plexus in aging male rats. ICP and CSF secretion rate and absorption capacity remain stable with age, and the choroid plexus retains its morphology, structural integrity, gene expression, and high metabolic rate across the tested ages. This work supports the significance of choroid plexus function for brain aging and promotes this tissue as a future target for neurodegenerative diseases associated with impaired waste clearance and cognitive decline.


  • Open Access

    Comprehensive Analysis of the 5xFAD Mouse Model of Alzheimer’s Disease Using dMRI, Immunohistochemistry, and Neuronal and Glial Functional Metabolic Mapping

    by Emil W. Westi, Saba Molhemi, Caroline Termøhlen Hansen, Christian Stald Skoven, Rasmus West Knopper, Dashne Amein Ahmad, Maja B. Rindshøj, Aishat O. Ameen, Brian Hansen, Kristi A. Kohlmeier, et al.

    Alzheimer’s disease (AD) is characterized by complex interactions between neuropathological markers, metabolic dysregulation, and structural brain changes. In this study, we utilized a multimodal approach, combining immunohistochemistry, functional metabolic mapping, and microstructure sensitive diffusion MRI (dMRI) to progressively investigate these interactions in the 5xFAD mouse model of AD. Our analysis revealed age-dependent and region-specific accumulation of key AD markers, including amyloid-beta (Aβ), GFAP, and IBA1, with significant differences observed between the hippocampal formation and upper and lower regions of the cortex by 6 months of age. Functional metabolic mapping validated localized disruptions in energy metabolism, with glucose hypometabolism in the hippocampus and impaired astrocytic metabolism in the cortex. Notably, increased cortical glutaminolysis suggested a shift in microglial metabolism, reflecting an adaptive response to neuroinflammatory processes. While dMRI showed no significant microstructural differences between 5xFAD and wild-type controls, the study highlights the importance of metabolic alterations as critical events in AD pathology. These findings emphasize the need for targeted therapeutic strategies addressing specific metabolic disturbances and underscore the potential of integrating advanced imaging with metabolic and molecular analyses to advance our understanding of AD progression.


  • Open Access

    Deficient brain GABA metabolism leads to widespread impairments of astrocyte and oligodendrocyte function

    by Jens V. Andersen, Oana C. Marian, Filippa L. Qvist, Emil W. Westi, Blanca I. Aldana, Arne Schousboe, Anthony S. Don, Niels H. Skotte, Petrine Wellendorph

    The neurometabolic disorder succinic semialdehyde dehydrogenase (SSADH) deficiency leads to great neurochemical imbalances and severe neurological manifestations. The cause of the disease is loss of function of the enzyme SSADH, leading to impaired metabolism of the principal inhibitory neurotransmitter GABA. Despite the known identity of the enzymatic deficit, the underlying pathology of SSADH deficiency remains unclear. To uncover new mechanisms of the disease, we performed an untargeted integrative analysis of cerebral protein expression, functional metabolism, and lipid composition in a genetic mouse model of SSADH deficiency (ALDH5A1 knockout mice). Our proteomic analysis revealed a clear regional vulnerability, as protein alterations primarily manifested in the hippocampus and cerebral cortex of the ALDH5A1 knockout mice. These regions displayed aberrant expression of proteins linked to amino acid homeostasis, mitochondria, glial function, and myelination. Stable isotope tracing in acutely isolated brain slices demonstrated an overall maintained oxidative metabolism of glucose, but a selective decrease in astrocyte metabolic activity in the cerebral cortex of ALDH5A1 knockout mice. In contrast, an elevated capacity of oxidative glutamine metabolism was observed in the ALDH5A1 knockout brain, which may serve as a neuronal compensation of impaired astrocyte glutamine provision. In addition to reduced expression of critical oligodendrocyte proteins, a severe depletion of myelin‐enriched sphingolipids was found in the brains of ALDH5A1 knockout mice, suggesting degeneration of myelin. Altogether, our study highlights that impaired astrocyte and oligodendrocyte function is intimately linked to SSADH deficiency pathology, suggesting that selective targeting of glial cells may hold therapeutic potential in this disease.


  • β-Hydroxybutyrate and Medium-Chain Fatty Acids are Metabolized by Different Cell Types in Mouse Cerebral Cortex Slices

    by Jens V. Andersen, Emil W. Westi, Elliott S. Neal, Blanca I. Aldana, Karin Borges

    Ketogenic diets and medium-chain triglycerides are gaining attention as treatment of neurological disorders. Their major metabolites, β-hydroxybutyrate (βHB) and the medium-chain fatty acids (MCFAs) octanoic acid (C8) and decanoic acid (C10), are auxiliary brain fuels. To which extent these fuels compete for metabolism in different brain cell types is unknown. Here, we used acutely isolated mouse cerebral cortical slices to (1) compare metabolism of 200 µM [U-13C]C8, [U-13C]C10 and [U-13C]βHB and (2) assess potential competition between metabolism of βHB and MCFAs by quantifying metabolite 13C enrichment using gas chromatography-mass spectrometry (GC–MS) analysis. The 13C enrichment in most metabolites was similar with [U-13C]C8 and [U-13C]C10 as substrates, but several fold lower with [U-13C]βHB. The 13C enrichment in glutamate was in a similar range for all three substrates, whereas the 13C enrichments in citrate and glutamine were markedly higher with both [U-13C]C8 and [U-13C]C10 compared with [U-13C]βHB. As citrate and glutamine are indicators of astrocytic metabolism, the results indicate active MCFA metabolism in astrocytes, while βHB is metabolized in a different cellular compartment. In competition experiments, 12C-βHB altered 13C incorporation from [U-13C]C8 and [U-13C]C10 in only a few instances, while 12C-C8 and 12C-C10 only further decreased the low [U-13C]βHB-derived 13C incorporation into citrate and glutamine, signifying little competition for oxidative metabolism between βHB and the MCFAs. Overall, the data demonstrate that βHB and MCFAs are supplementary fuels in different cellular compartments in the brain without notable competition. Thus, the use of medium-chain triglycerides in ketogenic diets is likely to be beneficial in conditions with carbon and energy shortages in both astrocytes and neurons, such as GLUT1 deficiency.